<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B936D768-A528-4ABB-A6FA-D5F91D6FD0F4"><gtr:id>B936D768-A528-4ABB-A6FA-D5F91D6FD0F4</gtr:id><gtr:name>Defence Science &amp; Technology Laboratory (DSTL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C5408F79-E297-4CFB-9A94-977B26D51DB3"><gtr:id>C5408F79-E297-4CFB-9A94-977B26D51DB3</gtr:id><gtr:firstName>Brendan</gtr:firstName><gtr:surname>Wren</gtr:surname><gtr:orcidId>0000-0002-6140-9489</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FH017437%2F1"><gtr:id>B01C9A6C-AE8F-42B3-92BB-4C97030D4211</gtr:id><gtr:title>A plethora of N-glycosylation pathways from the epsilon Proteobacteria - a resource for glycoprospecting and toolbox for glycoengineering</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/H017437/1</gtr:grantReference><gtr:abstractText>Glycoproteins (proteins that are modified with sugar structures) are ubiquitous biomolecules involved in most basic biological phenomena in complex living organisms such as humans, ranging from immune recognition to cancer development. They often have underestimated biological functions and in contrast to proteins and nucleic acids, glycans have escaped the cloning revolution. The experimentally tractable model bacterium Escherichia coli is often used as a 'cellular factory' to produce practically inexhaustible amounts of purified proteins for various uses. However, until recently it has not been possible to generate glycoproteins in this bacterium as these simple organisms do not make glycoproteins of this type. This how now changed. We recently identified and characterised a cluster of pgl genes which is responsible for the synthesis of glycoproteins in the simple gut bacterium Campylobacter jejuni. This is the first bacterium known to glycosylated their proteins in this way. Furthermore we have been able to transfer the segment of C. jejuni DNA containing the pgl genes into E. coli to produce recombinant glycoproteins, thus opening up the field of glycoengineering. The key enzyme in the C. jejuni pathway that couples proteins to sugars is the transferase protein termed CjPglB. Although CjPglB can transfer many sugar structures unfortunately there are many important glycostructures that it cannot. Recently we have identified dozens more bacteria that are related to C. jejuni that have different PglB sugar transferase enzymes. Indeed some of the bacteria have more than one PglB, the first time that this has been observed in bacteria, suggesting that they may have subtly different abilities to transfer different sugars and hence be invaluable for glycoengineering. In this proposal we wish to fully characterize the plethora of new PglB enzymes and their associated pathways to expand the range of genetic tools that could be used for glycoengineering. The proposal will also help answer fundamental questions as to why some bacteria require more than one PglB and the evolutionary origin of these unusual systems in bacteria. The program of work will benefit scientists interested in basic research and also in applied research particularly in the burgeoning glycobiotechnology industry.</gtr:abstractText><gtr:technicalSummary>We along with collaborators have characterized the first proven Bacterial N-linked glycosylation system in Campylobacter jejuni and subsequently transferred this system to E. coli to produce for the first time recombinant glycoproteins. The key enzyme in this process, encoded by the C. jejuni pglB gene, is the oligosaccharyltransferase that couples glycan to protein. Recently we have identified many more PglB-based bacterial glycosylation systems in species from the delta/epsilon Proteobacteria. These contain pglB genes associated with diverse sets of glycosyltransferases suggesting structural diversity in N-linked glycans. Some species encode two distinct PglB enzymes (a first for bacterial species) and may have dual glycosylation systems. This not only expands the range of PglB enzymes to investigate, but also provides novel glycostructures encoded by glycosyltransferases and associated enzymes within the variant Pgl pathways. We will (i) exploit a fluorescent peptide based assay for oligosaccharyltransferase activity to obtain PglB derived N-linked glycopeptides from a wide range of species for both structural analysis and to investigate the role of individual enzymes in glycan biosynthesis, (ii) explore the role of dual PglB glycosylation systems, (iii) identify novel glycoproteins in selected Helicobacter and Campylobacter species and (iv) further develop assays to screen the range of glycan specificity of diverse PglBs from the epsilon Proteobacteria. These studies will further our understanding of the evolution of N-linked glycosylation and act as tractable systems to understand more complex Eukaryotic N-linked glycosylation systems. Characterisation of novel oligosaccharyltransferases, associated glycosyltransferases and glycan structures in the Pgl pathways will expand our knowledge of these important enzymes and structures. Overall this will significantly contribute to the toolbox for glycoengineering with concomitant applications in glycobiotechnology.</gtr:technicalSummary><gtr:potentialImpactText>The impact of the proposed basic research is likely to be considerable in terms of glycoengineering and glycobiotechnology. For example, the most successful vaccines such as those that protect against the deadly bacteria Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae are glycoconjugate vaccines. However, using current technology it is difficult to produce and manufacture such vaccines requiring purification of the glycan from the native pathogen and chemical coupling to a protein carrier. Our pioneering studies on the PglBs and the demonstration that they can be used to produce recombinant glycans, promises to resolve these technological problems. Given that vaccination is a core public health measure in reducing the infectious disease burden, the proposed studies could make a highly significant impact for the health and well-being of both animals and humans. A longer-term impact would be to develop the Pgl-based technology for the modification of human proteins used as therapeutics in the Pharmaceutical industry. Although there are technological hurdles to overcome before this is a reality, the proposed research to understand the basic function of dual N-linked bacterial glycosylation systems will contribute to this long-term goal. The characterization of glycan biosynthetic pathways using the innovative fluorescent-labelled peptide system will impact synthetic biology approaches providing cassettes of genes that encode known glycan structures that could have diverse functions. We propose to disseminate our studies through publication in international peer-reviewed journals (where the applicants have a strong record) and by poster and oral presentations at major national and international meetings. The applicants have a track record of communicating the results of their research to the public and the mass media. Where possible these links will be used to promote this research. The potential impact of the research will also be realised though our respective technology transfer offices, material transfer agreements and patents. We will continue to collaborate with Glycovaxyn, a 40+SME dedicated to the design and manufacture of glycoconjugate vaccines using PglB-based technology. Glycovaxyn and other potential biotechnology companies with an interest in glycoengineering and/or vaccine development would provide the route to realize the potential of the proposed work subject to appropriate licensing agreements. Currently, we have an international lead in the study and exploitation of bacterial N-linked protein glycosylation systems and it is imperative that we continue these basic studies coupled with glycotool development to maintain this lead.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-10-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2010-10-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>317388</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Defence Science &amp; Technology Laboratory (DSTL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Vaccine development for defence purposes</gtr:description><gtr:id>31CE74EE-4F94-4114-BB78-836445FC11B3</gtr:id><gtr:impact>Several vaccine candidates tested and some may go forward to vaccine trials</gtr:impact><gtr:outcomeId>56d85e7cbde373.68197237-1</gtr:outcomeId><gtr:partnerContribution>Technology know how, specific animal testing facilities</gtr:partnerContribution><gtr:piContribution>New vaccine technology platform for making glycoconjugate vaccines against Burkholderia pseudomallei and Francisella tulerensis</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Broadcast interviews (Newsnight, Panorama, One Show)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>160557B5-DE74-4F96-8A1E-5CC518652CE2</gtr:id><gtr:impact>Interest in research at LSHTM

Better understanding of science</gtr:impact><gtr:outcomeId>5455263583d984.49989354</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DSTL Glycoconjugate vaccine design</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:id>BD68D8E2-A825-4F76-AF77-E4B35E259377</gtr:id><gtr:outcomeId>54551c7554f456.65551575</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>DSTL Glycoconjugate vaccine design for Coxiella</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Defence Science &amp; Technology Laboratory (DSTL)</gtr:fundingOrg><gtr:id>FAC2EFDB-F993-47BC-9CD5-076D6FCB7463</gtr:id><gtr:outcomeId>54551edeae7208.27281815</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Glycoengineering of Veterinary Vaccines</gtr:description><gtr:end>2021-04-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N001591/1</gtr:fundingRef><gtr:id>611B9DE9-E58F-4396-A0CD-4E13DF0B994B</gtr:id><gtr:outcomeId>56c762fd5f0de2.88479045</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developing and expanding the bacterial glycotoolbox for animal pathogens</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M01925X/1</gtr:fundingRef><gtr:id>44A805C6-9F5B-43C4-824C-8CD71109D945</gtr:id><gtr:outcomeId>56c761c21ed8d2.32559070</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Gates Grand Challenge</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>A7D71462-1DD3-485F-A4BB-065CF2927033</gtr:id><gtr:outcomeId>54551f8d797db1.68552204</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method to improve glycosylation of proteins</gtr:description><gtr:grantRef>BB/H017437/1</gtr:grantRef><gtr:id>17BF0838-1707-42E7-966E-B87F7F4A076B</gtr:id><gtr:impact>A method that could produce inexpensive glycoproteins</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54552e77d25269.40892190</gtr:outcomeId><gtr:patentId>WO3409P</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>MAGIC Mobile-element Assisted Glycoconjugate Insertion on Chromosome</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Novel method to construct combinations of glycoconjugate vaccines</gtr:description><gtr:grantRef>BB/H017437/1</gtr:grantRef><gtr:id>B9E13A92-6A6F-4C66-999E-19EE300F0957</gtr:id><gtr:impact>Can cheaply produce novel glycoconjugate vaccines for humans and animals</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54552937c18b49.27651853</gtr:outcomeId><gtr:patentId>WO4307P</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Glycoconjugate Vaccines</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>A large number of proteins in biological systems are modified with sugars, ie the proteins are glycosylated to form glycoproteins. Glycoproteins and the associated glycan structures are ubiquitous biomolecules involved in many biological processes ranging from immune recognition to cancer development. It has become clear that glycan structures have important, often underestimated biological functions. In contrast to protein and DNA, glycoproteins have escaped biotechnological applications so far. This is primarily due to the complexity of these essential biosynthetic pathways in mammailian cells. Comparison of well-characterised protein sequence database entries indicates that more than half of all proteins in nature will eventually be identified as glycoproteins. Glycoengineering-the synthesis of novel glyco-structures-is essential for studies to elucidate the crucial role of glycosylation in many aspects of biology. Glycoengineering is in its infancy, and with few suitable glycosylation pathways known in bacteria, producing recombinant glycoproteins in simple workhorse hosts such as E. coli has not been possible. 

We have identified an N-linked general glycosylation pathway in bacteria from the epsilon proteobacteria that can add sugar structures to proteins to produce glycoproteins. 

 Thus an aim of this study was to characterise further general glycosylation systems among the epsilon proteobacteria . We identified and characterised three novel N-linked system from bacteria found in deep-sea vents found in some oceans. These appear to have different specificity and useful additions to the &amp;quot;Glyco-toolbox&amp;quot;</gtr:description><gtr:exploitationPathways>We have identified an N-linked general glycosylation pathway in bacteria from the epsilon proteobacteria that can add sugar structures to proteins to produce glycoproteins. We have been able to clone this pathway into E. coli to produce recombinant glycoproteins. This discovery has hadenormous advantages to tailor make production-line quality glycoproteins that are required in industry and medicine.</gtr:exploitationPathways><gtr:id>856ABD25-0A90-458B-8CA2-857C0F1E5D85</gtr:id><gtr:outcomeId>54560d9b2e2ee0.21677024</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>16E75254-6AE0-4DAC-B5D0-69D1865C71F6</gtr:id><gtr:title>Functional analysis of N-linking oligosaccharyl transferase enzymes encoded by deep-sea vent proteobacteria.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9423ad96824837353871345c69fef24"><gtr:id>c9423ad96824837353871345c69fef24</gtr:id><gtr:otherNames>Mills DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>56c75cd00cb462.11247969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08F571E1-3D0A-4397-8C3C-7FFC1CBD5053</gtr:id><gtr:title>Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design.</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/412559f6c6101d7b8cf55f8e2bff9549"><gtr:id>412559f6c6101d7b8cf55f8e2bff9549</gtr:id><gtr:otherNames>Terra VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn><gtr:outcomeId>5449053c37acf0.22971966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB81E1B2-537A-4997-94FC-BF18A81347A0</gtr:id><gtr:title>Chromosomal integration vectors allowing flexible expression of foreign genes in Campylobacter jejuni.</gtr:title><gtr:parentPublicationTitle>BMC microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e2bbb7beecfcd6f92aad58eab45871"><gtr:id>90e2bbb7beecfcd6f92aad58eab45871</gtr:id><gtr:otherNames>Jervis AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2180</gtr:issn><gtr:outcomeId>56c75ccf896c90.11975083</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08CAE70D-1D02-452C-B378-A1896D7EE05A</gtr:id><gtr:title>Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins.</gtr:title><gtr:parentPublicationTitle>The Journal of pharmacy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42ea7ffb88b2aca6dd799ae28598e471"><gtr:id>42ea7ffb88b2aca6dd799ae28598e471</gtr:id><gtr:otherNames>Cuccui J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3573</gtr:issn><gtr:outcomeId>5448f16412b3e9.63488703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C81FCB4-F2D5-43AC-A0F6-862CE8E3F473</gtr:id><gtr:title>Functional analysis of the Helicobacter pullorum N-linked protein glycosylation system.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e2bbb7beecfcd6f92aad58eab45871"><gtr:id>90e2bbb7beecfcd6f92aad58eab45871</gtr:id><gtr:otherNames>Jervis AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>5a8987aa082b55.11788944</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95188CB4-834E-4AFA-9D8C-AB891CDEFA1E</gtr:id><gtr:title>The importance of the glycosylation of antimicrobial peptides: natural and synthetic approaches.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60cf49b532d87b3550d036e1c995d76c"><gtr:id>60cf49b532d87b3550d036e1c995d76c</gtr:id><gtr:otherNames>Bednarska NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>58ac152ff27f68.75916499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4CC5B31-726E-458D-B83C-2817DB8DBA5E</gtr:id><gtr:title>Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42ea7ffb88b2aca6dd799ae28598e471"><gtr:id>42ea7ffb88b2aca6dd799ae28598e471</gtr:id><gtr:otherNames>Cuccui J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>544903110c5437.16598191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B3EC4C8-43EA-4E35-A373-73B6C3DBFF39</gtr:id><gtr:title>Characterization of the structurally diverse N-linked glycans of Campylobacter species.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e2bbb7beecfcd6f92aad58eab45871"><gtr:id>90e2bbb7beecfcd6f92aad58eab45871</gtr:id><gtr:otherNames>Jervis AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>5449053d100ed0.97610312</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/H017437/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>